PURPOSE: This investigation sought to evaluate the prognostic value of pretreatment of circulating tumor DNA (ctDNA) in metastatic biliary tract cancers (BTCs) treated with platinum-based first-line chemotherapy treatment. MATERIALS AND METHODS: We performed a retrospective analysis of 67 patients who underwent ctDNA testing before platinum-based chemotherapy for first-line treatment for metastatic BTC. For analysis, we considered the detected gene with highest variant allele frequency as the dominant clone allele frequency (DCAF). Results of ctDNA analysis were correlated with patients' demographics, progression-free survival (PFS), and overall survival (OS). RESULTS: The median age of patients was 67 (27-90) years. Fifty-four (80.6%) of 67 patients evaluated had intrahepatic cholangiocarcinoma; seven had extrahepatic cholangiocarcinoma, and six gallbladder cancers. Forty-six (68.6%) of the patients were treated with cisplatin plus gemcitabine, and 16.4% of patients received gemcitabine and other platinum (carboplatin or oxaliplatin) combinations, whereas 15% of patients were treated on a clinical trial with gemcitabine and cisplatin plus additional agents (CX4945, PEGPH20, or nab-paclitaxel). TP53, KRAS, FGFR2, ARID1A, STK11, and IDH1 were the genes with highest frequency as DCAF. The median DCAF was 3% (0%-97%). DCAF > 3% was associated with worse OS (median OS: 10.8 v 18.8 months, P = .032). Stratifying DCAF in quartiles, DCAF > 10% was significantly related to worse PFS (median PFS: 3 months, P = .014) and worse OS (median OS: 7.0 months, P = .001). Each 1% increase in ctDNA was associated with a hazard ratio of 13.1 in OS when adjusting for subtypes, metastatic sites, size of largest tumor, age, sex, and CA19-9. CONCLUSION: DCAF at diagnosis of advanced BTC can stratify patients who have worse outcomes when treated with upfront platinum-based chemotherapy. Each increase in %ctDNA decreases survival probabilities.
PURPOSE: This investigation sought to evaluate the prognostic value of pretreatment of circulating tumor DNA (ctDNA) in metastatic biliary tract cancers (BTCs) treated with platinum-based first-line chemotherapy treatment. MATERIALS AND METHODS: We performed a retrospective analysis of 67 patients who underwent ctDNA testing before platinum-based chemotherapy for first-line treatment for metastatic BTC. For analysis, we considered the detected gene with highest variant allele frequency as the dominant clone allele frequency (DCAF). Results of ctDNA analysis were correlated with patients' demographics, progression-free survival (PFS), and overall survival (OS). RESULTS: The median age of patients was 67 (27-90) years. Fifty-four (80.6%) of 67 patients evaluated had intrahepatic cholangiocarcinoma; seven had extrahepatic cholangiocarcinoma, and six gallbladder cancers. Forty-six (68.6%) of the patients were treated with cisplatin plus gemcitabine, and 16.4% of patients received gemcitabine and other platinum (carboplatin or oxaliplatin) combinations, whereas 15% of patients were treated on a clinical trial with gemcitabine and cisplatin plus additional agents (CX4945, PEGPH20, or nab-paclitaxel). TP53, KRAS, FGFR2, ARID1A, STK11, and IDH1 were the genes with highest frequency as DCAF. The median DCAF was 3% (0%-97%). DCAF > 3% was associated with worse OS (median OS: 10.8 v 18.8 months, P = .032). Stratifying DCAF in quartiles, DCAF > 10% was significantly related to worse PFS (median PFS: 3 months, P = .014) and worse OS (median OS: 7.0 months, P = .001). Each 1% increase in ctDNA was associated with a hazard ratio of 13.1 in OS when adjusting for subtypes, metastatic sites, size of largest tumor, age, sex, and CA19-9. CONCLUSION: DCAF at diagnosis of advanced BTC can stratify patients who have worse outcomes when treated with upfront platinum-based chemotherapy. Each increase in %ctDNA decreases survival probabilities.
Authors: Lipika Goyal; Supriya K Saha; Leah Y Liu; Giulia Siravegna; Ignaty Leshchiner; Leanne G Ahronian; Jochen K Lennerz; Phuong Vu; Vikram Deshpande; Avinash Kambadakone; Benedetta Mussolin; Stephanie Reyes; Laura Henderson; Jiaoyuan Elisabeth Sun; Emily E Van Seventer; Joseph M Gurski; Sabrina Baltschukat; Barbara Schacher-Engstler; Louise Barys; Christelle Stamm; Pascal Furet; David P Ryan; James R Stone; A John Iafrate; Gad Getz; Diana Graus Porta; Ralph Tiedt; Alberto Bardelli; Dejan Juric; Ryan B Corcoran; Nabeel Bardeesy; Andrew X Zhu Journal: Cancer Discov Date: 2016-12-29 Impact factor: 39.397
Authors: Richard B Lanman; Stefanie A Mortimer; Oliver A Zill; Dragan Sebisanovic; Rene Lopez; Sibel Blau; Eric A Collisson; Stephen G Divers; Dave S B Hoon; E Scott Kopetz; Jeeyun Lee; Petros G Nikolinakos; Arthur M Baca; Bahram G Kermani; Helmy Eltoukhy; AmirAli Talasaz Journal: PLoS One Date: 2015-10-16 Impact factor: 3.240
Authors: Marin Strijker; Eline C Soer; Matteo de Pastena; Aafke Creemers; Alberto Balduzzi; Jamie J Beagan; Olivier R Busch; Otto M van Delden; Hans Halfwerk; Jeanin E van Hooft; Krijn P van Lienden; Giovanni Marchegiani; Sybren L Meijer; Carel J van Noesel; Roy J Reinten; Eva Roos; Sandor Schokker; Joanne Verheij; Marc J van de Vijver; Cynthia Waasdorp; Johanna W Wilmink; Bauke Ylstra; Marc G Besselink; Maarten F Bijlsma; Frederike Dijk; Hanneke W van Laarhoven Journal: Int J Cancer Date: 2019-08-13 Impact factor: 7.396
Authors: Ryosuke Okamura; Razelle Kurzrock; Robert J Mallory; Paul T Fanta; Adam M Burgoyne; Bryan M Clary; Shumei Kato; Jason K Sicklick Journal: Int J Cancer Date: 2020-08-28 Impact factor: 7.396
Authors: Arvind Dasari; Van K Morris; Carmen J Allegra; Chloe Atreya; Al B Benson; Patrick Boland; Ki Chung; Mehmet S Copur; Ryan B Corcoran; Dustin A Deming; Andrea Dwyer; Maximilian Diehn; Cathy Eng; Thomas J George; Marc J Gollub; Rachel A Goodwin; Stanley R Hamilton; Jaclyn F Hechtman; Howard Hochster; Theodore S Hong; Federico Innocenti; Atif Iqbal; Samuel A Jacobs; Hagen F Kennecke; James J Lee; Christopher H Lieu; Heinz-Josef Lenz; O Wolf Lindwasser; Clara Montagut; Bruno Odisio; Fang-Shu Ou; Laura Porter; Kanwal Raghav; Deborah Schrag; Aaron J Scott; Qian Shi; John H Strickler; Alan Venook; Rona Yaeger; Greg Yothers; Y Nancy You; Jason A Zell; Scott Kopetz Journal: Nat Rev Clin Oncol Date: 2020-07-06 Impact factor: 65.011
Authors: Carolyn Cullinane; Christina Fleming; Donal Peter O'Leary; Fara Hassan; Louise Kelly; Martin J O'Sullivan; Mark Antony Corrigan; Henry Paul Redmond Journal: JAMA Netw Open Date: 2020-11-02